{"hands_on_practices": [{"introduction": "A crucial first step in any clinical development program is determining a safe starting dose for first-in-human trials. This practice will guide you through the standard regulatory method of translating a no-observed-adverse-effect level (NOAEL) from animal studies into a Human Equivalent Dose (HED). You will apply the principle of body surface area scaling, a cornerstone of inter-species toxicology, to ensure that the initial dose administered to human volunteers is both cautious and informed by preclinical data [@problem_id:4943009].", "problem": "A sponsor is preparing a first-in-human clinical trial and needs to translate a rat no-observed-adverse-effect level (NOAEL) to a human equivalent dose (HED) using the body surface area scaling approach that is widely used in regulatory pharmacology. Body surface area scaling relies on the observation that pharmacological and toxicological responses correlate more closely with dose per unit body surface area than with dose per unit body mass across mammalian species. Let the mass-to-surface conversion coefficient $K_{m}$ be defined as the ratio of average body mass to average body surface area for a species, which has units of $\\mathrm{kg}/\\mathrm{m}^{2}$. By dimensional analysis, a dose per body surface area in $\\mathrm{mg}/\\mathrm{m}^{2}$ can be obtained by multiplying a dose per body mass in $\\mathrm{mg}/\\mathrm{kg}$ by the appropriate $K_{m}$ for that species.\n\nGiven a rat NOAEL of $20$ mg/kg, a rat $K_{m}^{\\text{rat}} = 6$, and an adult human $K_{m}^{\\text{human}} = 37$, derive from these definitions an expression to compute the human equivalent dose $D_{\\text{HED}}$ in $\\mathrm{mg}/\\mathrm{kg}$ that produces comparable exposure on a body surface area basis. Then apply a $10$-fold safety factor to propose a conservative first-in-human starting dose $D_{\\text{start}}$ in $\\mathrm{mg}/\\mathrm{kg}$.\n\nExpress your final numerical answer for $D_{\\text{start}}$ in $\\mathrm{mg}/\\mathrm{kg}$, and round to four significant figures.", "solution": "The problem statement is first validated for scientific soundness, clarity, and completeness.\n\n### Step 1: Extracted Givens\n- Rat no-observed-adverse-effect level, $D_{\\text{rat}} = 20$ mg/kg.\n- Rat mass-to-surface conversion coefficient, $K_{m}^{\\text{rat}} = 6\\ \\mathrm{kg}/\\mathrm{m}^2$.\n- Adult human mass-to-surface conversion coefficient, $K_{m}^{\\text{human}} = 37\\ \\mathrm{kg}/\\mathrm{m}^2$.\n- Definition of $K_m$: The ratio of average body mass to average body surface area for a species.\n- Conversion rule: A dose per body surface area (in $\\mathrm{mg}/\\mathrm{m}^{2}$) is obtained by multiplying a dose per body mass (in $\\mathrm{mg}/\\mathrm{kg}$) by the species-specific $K_m$.\n- Safety factor, $SF = 10$.\n- Objective 1: Derive an expression for the human equivalent dose, $D_{\\text{HED}}$, in $\\mathrm{mg}/\\mathrm{kg}$.\n- Objective 2: Calculate a conservative first-in-human starting dose, $D_{\\text{start}}$, in $\\mathrm{mg}/\\mathrm{kg}$.\n- Rounding instruction: The final numerical answer for $D_{\\text{start}}$ must be rounded to four significant figures.\n\n### Step 2: Validation\nThe problem is scientifically grounded. The use of body surface area (BSA) scaling for interspecies dose conversion is a standard and well-established methodology in regulatory toxicology and pharmacology, recommended by agencies such as the U.S. Food and Drug Administration (FDA) for estimating the maximum recommended starting dose (MRSD) in first-in-human clinical trials. The problem is well-posed, providing all necessary definitions and data ($D_{\\text{rat}}$, $K_m$ values, and the safety factor) to compute a unique solution. The language is objective and unambiguous. The problem does not violate any principles of scientific logic, is not incomplete or contradictory, and is directly formalizable.\n\n### Step 3: Verdict\nThe problem is **valid**. A solution will be derived.\n\n### Derivation\nThe core principle of body surface area (BSA) scaling is that the dose level that produces a specific pharmacological or toxicological effect is equivalent across species when expressed in units of mass per unit of body surface area (e.g., $\\mathrm{mg}/\\mathrm{m}^{2}$).\n\nLet $D_{\\text{rat, BSA}}$ be the dose in the rat expressed in $\\mathrm{mg}/\\mathrm{m}^{2}$ and $D_{\\text{human, BSA}}$ be the equivalent dose in the human, also in $\\mathrm{mg}/\\mathrm{m}^{2}$. The principle states:\n$$D_{\\text{human, BSA}} = D_{\\text{rat, BSA}}$$\n\nThe problem provides the formula to convert a dose given in mass per unit body mass ($D_{\\text{mass}}$, in $\\mathrm{mg}/\\mathrm{kg}$) to a dose in mass per unit body surface area ($D_{\\text{BSA}}$) using the species-specific conversion coefficient $K_m$:\n$$D_{\\text{BSA}} = D_{\\text{mass}} \\times K_m$$\n\nApplying this conversion to both the rat and human species:\nFor the rat, the NOAEL is $D_{\\text{rat}} = 20$ mg/kg. The BSA-based dose is:\n$$D_{\\text{rat, BSA}} = D_{\\text{rat}} \\times K_{m}^{\\text{rat}}$$\n\nFor the human, the human equivalent dose is $D_{\\text{HED}}$ (in $\\mathrm{mg}/\\mathrm{kg}$). The BSA-based dose is:\n$$D_{\\text{human, BSA}} = D_{\\text{HED}} \\times K_{m}^{\\text{human}}$$\n\nEquating the two BSA-based doses gives the relationship:\n$$D_{\\text{HED}} \\times K_{m}^{\\text{human}} = D_{\\text{rat}} \\times K_{m}^{\\text{rat}}$$\n\nThe first objective is to derive an expression for $D_{\\text{HED}}$. We can achieve this by isolating $D_{\\text{HED}}$:\n$$D_{\\text{HED}} = D_{\\text{rat}} \\times \\frac{K_{m}^{\\text{rat}}}{K_{m}^{\\text{human}}}$$\nThis is the general expression for the human equivalent dose based on the provided definitions.\n\nThe second objective is to apply a $10$-fold safety factor to determine a conservative first-in-human starting dose, $D_{\\text{start}}$. A safety factor is applied to reduce the risk of adverse effects in humans by starting at a dose significantly lower than the calculated HED.\nLet the safety factor be $SF = 10$.\n$$D_{\\text{start}} = \\frac{D_{\\text{HED}}}{SF}$$\n\nSubstituting the expression for $D_{\\text{HED}}$ into the equation for $D_{\\text{start}}$:\n$$D_{\\text{start}} = \\frac{1}{SF} \\left( D_{\\text{rat}} \\times \\frac{K_{m}^{\\text{rat}}}{K_{m}^{\\text{human}}} \\right)$$\n\nNow, we can substitute the given numerical values into this expression:\n- $D_{\\text{rat}} = 20\\ \\mathrm{mg}/\\mathrm{kg}$\n- $K_{m}^{\\text{rat}} = 6\\ \\mathrm{kg}/\\mathrm{m}^2$\n- $K_{m}^{\\text{human}} = 37\\ \\mathrm{kg}/\\mathrm{m}^2$\n- $SF = 10$\n\n$$D_{\\text{start}} = \\frac{1}{10} \\left( 20 \\text{ mg/kg} \\times \\frac{6}{37} \\right)$$\n$$D_{\\text{start}} = \\frac{20 \\times 6}{10 \\times 37} \\text{ mg/kg} = \\frac{120}{370} \\text{ mg/kg} = \\frac{12}{37} \\text{ mg/kg}$$\n\nTo obtain the final numerical answer, we perform the division and round to four significant figures as requested.\n$$D_{\\text{start}} = \\frac{12}{37} \\approx 0.324324324... \\text{ mg/kg}$$\nRounding to four significant figures gives:\n$$D_{\\text{start}} \\approx 0.3243 \\text{ mg/kg}$$", "answer": "$$\\boxed{0.3243}$$", "id": "4943009"}, {"introduction": "Once a drug enters Phase I clinical trials, particularly in oncology, the primary goal is often to find the Maximum Tolerated Dose (MTD). This exercise delves into the statistical logic of the widely used \"$3+3$\" dose-escalation design, a rule-based algorithm for carefully increasing doses while monitoring for toxicity. By deriving its implied target toxicity rate, you will gain a deeper appreciation for the risk-benefit balance that is hard-wired into this foundational clinical trial methodology [@problem_id:4943054].", "problem": "A dose-escalation algorithm widely used in early-phase oncology trials that support Investigational New Drug (IND) applications prior to regulatory review by the United States Food and Drug Administration (FDA) is the “$3{+}3$” design. The algorithm proceeds by treating patients in cohorts of $3$ at increasing dose levels to identify a Maximum Tolerated Dose (MTD), defined operationally as the highest dose at which the observed dose-limiting toxicity (DLT) frequency is within prespecified acceptability. For this problem, formalize the $3{+}3$ algorithm’s cohort-level decision-making at a given dose as follows, using precise probabilistic language and symbols: treat $3$ patients at a dose; escalate if $0$ of $3$ patients experience DLT; expand the cohort to $6$ at the same dose if $1$ of $3$ patients experiences DLT; and de-escalate (do not treat additional patients at this dose) if $2$ or $3$ of $3$ patients experience DLT. Under a simple model in which each treated patient at the current dose independently experiences a DLT with probability $p \\in (0,1)$ and without DLT with probability $1-p$, treat the number of DLTs in a cohort of $3$ patients as a binomial random variable.\n\nDefine the implied “target DLT rate” $p^{\\ast}$ for the $3{+}3$ algorithm at the cohort level to be the toxicity probability at which the algorithm is decision-neutral for escalation versus de-escalation after the first $3$ patients at a dose, in the sense that the probability of escalation equals the probability of de-escalation. Starting from the binomial model and the definition of the $3{+}3$ decision rules, derive and solve for $p^{\\ast}$ exactly.\n\nExpress your final answer as a single exact analytical expression; do not provide a numerical approximation, and do not include units.", "solution": "The problem asks for the derivation of the implied \"target DLT rate\" $p^{\\ast}$ for the $3+3$ dose-escalation algorithm. This target rate is defined as the toxicity probability $p$ at which the probability of escalating to a higher dose is equal to the probability of de-escalating (i.e., stopping treatment at the current dose).\n\nFirst, we formalize the probabilistic model. Let $X$ be the random variable representing the number of patients who experience a dose-limiting toxicity (DLT) in a cohort of $n=3$ patients at a given dose level. The problem states that each patient independently experiences a DLT with probability $p$, where $p \\in (0,1)$. Therefore, $X$ follows a binomial distribution with parameters $n=3$ and $p$, denoted as $X \\sim \\text{Binomial}(3, p)$.\n\nThe probability mass function (PMF) for $X$ is given by:\n$$P(X=k) = \\binom{n}{k} p^k (1-p)^{n-k}$$\nFor this problem, with $n=3$, the PMF is:\n$$P(X=k) = \\binom{3}{k} p^k (1-p)^{3-k} \\quad \\text{for } k \\in \\{0, 1, 2, 3\\}$$\n\nNext, we translate the decision rules of the $3+3$ algorithm into probabilistic statements based on the outcome of the first cohort of $3$ patients.\n1.  **Escalation:** The algorithm dictates escalation to the next dose level if $0$ out of $3$ patients experience a DLT. The probability of this event, $P(\\text{Escalate})$, is:\n    $$P(\\text{Escalate}) = P(X=0)$$\n2.  **De-escalation:** The algorithm dictates de-escalation (stopping treatment at the current dose) if $2$ or $3$ out of $3$ patients experience a DLT. The probability of this event, $P(\\text{De-escalate})$, is the sum of the probabilities of these two mutually exclusive outcomes:\n    $$P(\\text{De-escalate}) = P(X=2) + P(X=3) = P(X \\ge 2)$$\n3.  **Expansion:** The algorithm dictates expanding the cohort to $6$ patients at the same dose if $1$ out of $3$ patients experiences a DLT. The probability of this event is $P(X=1)$. This rule is not directly involved in the calculation of $p^{\\ast}$ as defined by the problem.\n\nThe target DLT rate $p^{\\ast}$ is defined as the value of $p$ for which the probability of escalation equals the probability of de-escalation:\n$$P(\\text{Escalate}) = P(\\text{De-escalate})$$\nSubstituting the expressions from above, we need to solve the following equation for $p$:\n$$P(X=0) = P(X \\ge 2)$$\n\nWe now use the binomial PMF to express these probabilities in terms of $p$:\nFor the left-hand side:\n$$P(X=0) = \\binom{3}{0} p^0 (1-p)^{3-0} = 1 \\cdot p^0 \\cdot (1-p)^3 = (1-p)^3$$\nFor the right-hand side:\n$$P(X=2) = \\binom{3}{2} p^2 (1-p)^{3-2} = 3p^2(1-p)^1 = 3p^2(1-p)$$\n$$P(X=3) = \\binom{3}{3} p^3 (1-p)^{3-3} = 1 \\cdot p^3 \\cdot (1-p)^0 = p^3$$\nSo, $P(X \\ge 2) = 3p^2(1-p) + p^3$.\n\nThe equation to solve for $p^{\\ast}$ becomes:\n$$(1-p)^3 = 3p^2(1-p) + p^3$$\nWe expand both sides and simplify. The left-hand side is $1 - 3p + 3p^2 - p^3$. The right-hand side is $3p^2 - 3p^3 + p^3 = 3p^2 - 2p^3$.\n$$1 - 3p + 3p^2 - p^3 = 3p^2 - 2p^3$$\nWe can cancel the $3p^2$ term from both sides and rearrange the equation to form a polynomial in $p$:\n$$1 - 3p - p^3 = -2p^3$$\n$$p^3 - 3p + 1 = 0$$\n\nThis is a cubic equation for $p$. We must find the root that lies in the physically meaningful interval $(0,1)$. Let $f(p) = p^3 - 3p + 1$. We note that $f(0) = 1$ and $f(1) = 1 - 3 + 1 = -1$. Since $f(p)$ is a continuous function and changes sign on the interval $(0,1)$, the Intermediate Value Theorem guarantees at least one root in this interval. The derivative is $f'(p) = 3p^2 - 3 = 3(p^2 - 1)$, which is strictly negative for all $p \\in (0,1)$. Thus, $f(p)$ is strictly decreasing on $(0,1)$, which ensures that there is exactly one root in this interval.\n\nTo solve the cubic equation $p^3 - 3p + 1 = 0$, we can use the trigonometric method. Let's try the substitution $p = 2\\sin(\\theta)$.\n$$(2\\sin(\\theta))^3 - 3(2\\sin(\\theta)) + 1 = 0$$\n$$8\\sin^3(\\theta) - 6\\sin(\\theta) + 1 = 0$$\n$$-2(3\\sin(\\theta) - 4\\sin^3(\\theta)) + 1 = 0$$\nUsing the triple-angle identity for sine, $\\sin(3\\theta) = 3\\sin(\\theta) - 4\\sin^3(\\theta)$, we get:\n$$-2\\sin(3\\theta) + 1 = 0$$\n$$\\sin(3\\theta) = \\frac{1}{2}$$\n\nThis equation for $\\theta$ yields general solutions for $3\\theta$:\n$$3\\theta = \\frac{\\pi}{6} + 2k\\pi \\quad \\text{or} \\quad 3\\theta = \\pi - \\frac{\\pi}{6} + 2k\\pi = \\frac{5\\pi}{6} + 2k\\pi$$\nwhere $k$ is an integer. Dividing by $3$, we get the solutions for $\\theta$:\n$$\\theta = \\frac{\\pi}{18} + \\frac{2k\\pi}{3} \\quad \\text{or} \\quad \\theta = \\frac{5\\pi}{18} + \\frac{2k\\pi}{3}$$\nWe need to find the value of $\\theta$ that gives a root $p = 2\\sin(\\theta)$ in the interval $(0,1)$.\nLet's examine the solutions for $k=0, 1, 2$:\nFor $k=0$:\n$\\theta = \\frac{\\pi}{18} \\implies p = 2\\sin(\\frac{\\pi}{18})$. Since $0 < \\frac{\\pi}{18} < \\frac{\\pi}{6}$, we have $0 < \\sin(\\frac{\\pi}{18}) < \\sin(\\frac{\\pi}{6})=\\frac{1}{2}$. Thus, $0 < p < 1$. This is a valid solution.\n$\\theta = \\frac{5\\pi}{18} \\implies p = 2\\sin(\\frac{5\\pi}{18})$. Since $\\frac{\\pi}{6} < \\frac{5\\pi}{18} < \\frac{\\pi}{2}$, we have $\\sin(\\frac{5\\pi}{18}) > \\sin(\\frac{\\pi}{6})=\\frac{1}{2}$. Thus, $p > 1$. This is not a valid solution.\n\nOther values of $k$ yield roots outside the required range. For instance, for $k=1$, $\\theta = \\frac{\\pi}{18} + \\frac{2\\pi}{3} = \\frac{13\\pi}{18}$, which gives $p = 2\\sin(\\frac{13\\pi}{18}) = 2\\sin(\\frac{5\\pi}{18}) > 1$. For $k=2$, $\\theta = \\frac{\\pi}{18} + \\frac{4\\pi}{3} = \\frac{25\\pi}{18}$, which lies in the third quadrant, making $\\sin(\\theta)$ negative and thus $p$ negative.\n\nThe unique solution for $p$ in the interval $(0,1)$ is therefore $p^{\\ast} = 2\\sin(\\frac{\\pi}{18})$.\nThis is the exact analytical expression for the target DLT rate.", "answer": "$$\\boxed{2\\sin\\left(\\frac{\\pi}{18}\\right)}$$", "id": "4943054"}, {"introduction": "The approval of generic drugs relies on demonstrating that they are bioequivalent to the original brand-name product, ensuring they can be substituted with confidence. This practice walks you through the formal statistical assessment of bioequivalence for pharmacokinetic parameters like $C_{\\max}$ and AUC. You will construct confidence intervals and apply the standard regulatory acceptance criteria, a key skill for understanding how generic drug applications are evaluated by agencies like the FDA and EMA [@problem_id:4943004].", "problem": "A sponsor submits a randomized, two-sequence, two-period crossover bioequivalence study comparing a test formulation to a reference formulation for a small-molecule drug. Assume log-normal pharmacokinetics and that the standard bioequivalence criterion requires that the $90\\%$ confidence intervals for the test-to-reference ratios of the maximum observed plasma concentration (Cmax) and the area under the concentration–time curve (AUC) lie entirely within $\\left[0.80, 1.25\\right]$ on the ratio scale. The study enrolled $N=24$ healthy adults with balanced sequences. On the natural logarithm scale, the model-based point estimates for the test-to-reference ratios are given by the geometric mean ratios $\\mathrm{GMR}_{\\mathrm{Cmax}}=0.95$ and $\\mathrm{GMR}_{\\mathrm{AUC}}=1.03$. The estimated within-subject standard deviations on the log scale are $s_{w,\\mathrm{Cmax}}=0.18$ and $s_{w,\\mathrm{AUC}}=0.10$. Use a two-sided $90\\%$ confidence interval based on the Student’s $t$ distribution with degrees of freedom $\\mathrm{df}=22$, for which the upper $5\\%$ point is $t_{0.95,22}=1.717$.\n\nStarting from fundamental definitions of variance for independent observations and the properties of the natural logarithm, derive the standard error for the estimated mean treatment difference on the log scale for each endpoint, construct the $90\\%$ confidence interval on the log scale, and then back-transform to the ratio scale to obtain the confidence intervals for Cmax and AUC. Assess pharmacokinetic (PK) similarity (bioequivalence) by checking whether both intervals lie entirely within $\\left[0.80,1.25\\right]$.\n\nReport your final result as a row matrix in the order $\\left[\\text{lower}_{\\mathrm{Cmax}},\\,\\text{upper}_{\\mathrm{Cmax}},\\,\\text{lower}_{\\mathrm{AUC}},\\,\\text{upper}_{\\mathrm{AUC}},\\,I\\right]$, where $I=1$ if both intervals are entirely within $\\left[0.80,1.25\\right]$ and $I=0$ otherwise. Express all four bounds as unitless decimal ratios relative to the reference formulation. Round all five reported values to three significant figures.", "solution": "The problem statement is evaluated and deemed valid. It is scientifically grounded in the principles of pharmacokinetics and biostatistics, specifically the standard methodology for assessing bioequivalence in a two-period crossover study. The problem is well-posed, providing all necessary data for a unique solution, including sample size, geometric mean ratios, within-subject variability, and the relevant critical value from the Student's $t$ distribution. The degrees of freedom $\\mathrm{df}=22$ are consistent with the sample size $N=24$ for a standard two-period crossover design analysis ($\\mathrm{df} = N-2 = 24-2=22$). The language is objective and the parameters are realistic.\n\nThe objective is to determine if a test formulation is bioequivalent to a reference formulation. Bioequivalence is assessed for two pharmacokinetic parameters: the maximum observed plasma concentration ($\\mathrm{Cmax}$) and the area under the concentration-time curve ($\\mathrm{AUC}$). The standard criterion for bioequivalence is that the $90\\%$ confidence interval for the ratio of the test formulation's geometric mean to the reference formulation's geometric mean must lie entirely within the range $[0.80, 1.25]$.\n\nThe analysis is performed on the natural logarithm of the pharmacokinetic data, as the problem assumes log-normal distribution of the parameters. Let $\\mu_T$ and $\\mu_R$ represent the population means of the log-transformed parameters for the test and reference formulations, respectively. The difference between these means is denoted by $\\delta = \\mu_T - \\mu_R$. The point estimate of this difference, $\\hat{\\delta}$, is the difference between the sample means on the log scale, which is equivalent to the natural logarithm of the geometric mean ratio (GMR).\n\nFor $\\mathrm{Cmax}$: $\\hat{\\delta}_{\\mathrm{Cmax}} = \\ln(\\mathrm{GMR}_{\\mathrm{Cmax}}) = \\ln(0.95)$.\nFor $\\mathrm{AUC}$: $\\hat{\\delta}_{\\mathrm{AUC}} = \\ln(\\mathrm{GMR}_{\\mathrm{AUC}}) = \\ln(1.03)$.\n\nThe next step is to derive the standard error (SE) for the estimated mean difference, $\\hat{\\delta}$. For a two-sequence, two-period crossover study with a total of $N$ subjects, the variance of the estimated treatment difference on the log scale is derived from the within-subject variance, $\\sigma_w^2$. The variance of the estimator $\\hat{\\delta}$ is given by $\\mathrm{Var}(\\hat{\\delta}) = \\frac{2\\sigma_w^2}{N}$. The standard error is the square root of the estimated variance, using the sample estimate $s_w^2$ for $\\sigma_w^2$:\n$$\n\\mathrm{SE}(\\hat{\\delta}) = \\sqrt{\\frac{2 s_w^2}{N}} = s_w \\sqrt{\\frac{2}{N}}\n$$\nGiven $N=24$, the term $\\sqrt{\\frac{2}{N}} = \\sqrt{\\frac{2}{24}} = \\sqrt{\\frac{1}{12}}$.\n\nWe can now calculate the standard error for each parameter:\nFor $\\mathrm{Cmax}$, with $s_{w,\\mathrm{Cmax}} = 0.18$:\n$$\n\\mathrm{SE}_{\\mathrm{Cmax}} = 0.18 \\sqrt{\\frac{1}{12}} = \\frac{0.18}{\\sqrt{12}}\n$$\nFor $\\mathrm{AUC}$, with $s_{w,\\mathrm{AUC}} = 0.10$:\n$$\n\\mathrm{SE}_{\\mathrm{AUC}} = 0.10 \\sqrt{\\frac{1}{12}} = \\frac{0.10}{\\sqrt{12}}\n$$\nA two-sided $90\\%$ confidence interval on the log scale is constructed using the formula:\n$$\n\\mathrm{CI}_{\\log} = \\hat{\\delta} \\pm t_{1-\\alpha/2, \\mathrm{df}} \\times \\mathrm{SE}(\\hat{\\delta})\n$$\nFor a $90\\%$ confidence interval, $\\alpha=0.10$, so $\\alpha/2 = 0.05$. The problem provides the critical value $t_{0.95, 22} = 1.717$, which corresponds to $t_{1-0.05, 22}$.\n\nThe confidence interval for the mean difference of log-transformed $\\mathrm{Cmax}$ is:\n$$\n\\mathrm{CI}_{\\log, \\mathrm{Cmax}} = \\ln(0.95) \\pm 1.717 \\times \\frac{0.18}{\\sqrt{12}}\n$$\nThe confidence interval for the mean difference of log-transformed $\\mathrm{AUC}$ is:\n$$\n\\mathrm{CI}_{\\log, \\mathrm{AUC}} = \\ln(1.03) \\pm 1.717 \\times \\frac{0.10}{\\sqrt{12}}\n$$\nTo obtain the confidence interval on the original ratio scale, we exponentiate the lower and upper bounds of the log-scale intervals.\n\nFor $\\mathrm{Cmax}$:\nLower bound: $\\text{lower}_{\\mathrm{Cmax}} = \\exp\\left(\\ln(0.95) - \\frac{1.717 \\times 0.18}{\\sqrt{12}}\\right) \\approx \\exp(-0.05129 - 0.08928) = \\exp(-0.14057) \\approx 0.86886$\nUpper bound: $\\text{upper}_{\\mathrm{Cmax}} = \\exp\\left(\\ln(0.95) + \\frac{1.717 \\times 0.18}{\\sqrt{12}}\\right) \\approx \\exp(-0.05129 + 0.08928) = \\exp(0.03799) \\approx 1.03871$\n\nFor $\\mathrm{AUC}$:\nLower bound: $\\text{lower}_{\\mathrm{AUC}} = \\exp\\left(\\ln(1.03) - \\frac{1.717 \\times 0.10}{\\sqrt{12}}\\right) \\approx \\exp(0.02956 - 0.04960) = \\exp(-0.02004) \\approx 0.98016$\nUpper bound: $\\text{upper}_{\\mathrm{AUC}} = \\exp\\left(\\ln(1.03) + \\frac{1.717 \\times 0.10}{\\sqrt{12}}\\right) \\approx \\exp(0.02956 + 0.04960) = \\exp(0.07916) \\approx 1.08238$\n\nRounding these bounds to three significant figures:\n$\\text{lower}_{\\mathrm{Cmax}} \\approx 0.869$\n$\\text{upper}_{\\mathrm{Cmax}} \\approx 1.04$\n$\\text{lower}_{\\mathrm{AUC}} \\approx 0.980$\n$\\text{upper}_{\\mathrm{AUC}} \\approx 1.08$\n\nFinally, we assess bioequivalence by checking if both confidence intervals lie entirely within the acceptance range of $[0.80, 1.25]$.\nThe $\\mathrm{Cmax}$ confidence interval is $[0.869, 1.04]$. Since $0.80 \\le 0.869$ and $1.04 \\le 1.25$, this interval is within the acceptance range.\nThe $\\mathrm{AUC}$ confidence interval is $[0.980, 1.08]$. Since $0.80 \\le 0.980$ and $1.08 \\le 1.25$, this interval is also within the acceptance range.\nSince both parameters meet the criterion, the test and reference formulations are considered bioequivalent. Therefore, the indicator variable $I$ is $1$. Rounding to three significant figures as requested for all five output values, $I=1.00$.\n\nThe final result is the row matrix $[\\text{lower}_{\\mathrm{Cmax}},\\,\\text{upper}_{\\mathrm{Cmax}},\\,\\text{lower}_{\\mathrm{AUC}},\\,\\text{upper}_{\\mathrm{AUC}},\\,I]$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.869 & 1.04 & 0.980 & 1.08 & 1.00\n\\end{pmatrix}\n}\n$$", "id": "4943004"}]}